Silvana Grasso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5443241/publications.pdf

Version: 2024-02-01

65 papers	2,196 citations	201385 27 h-index	233125 45 g-index
73 all docs	73 docs citations	73 times ranked	2014 citing authors

#	Article	IF	Citations
1	Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes. ChemMedChem, 2019, 14, 842-852.	1.6	18
2	Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 278-283.	1.0	8
3	Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. , 2018, 182, 176-192.		76
4	Development of novel N -3-bromoisoxazolin-5-yl substituted 2,3-benzodiazepines as noncompetitive AMPAR antagonists. Bioorganic and Medicinal Chemistry, 2017, 25, 3631-3637.	1.4	18
5	Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs). Journal of Medicinal Chemistry, 2017, 60, 6911-6923.	2.9	46
6	Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases. Current Medicinal Chemistry, 2016, 23, 1217-1238.	1.2	36
7	Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening. European Journal of Medicinal Chemistry, 2016, 121, 578-591.	2.6	21
8	Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3453-3456.	1.0	23
9	Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1184-1191.	2.5	27
10	NMR conformational analysis in solution of a potent class of cysteine proteases inhibitors. Structural Chemistry, 2015, 26, 943-950.	1.0	10
11	Mechanism and Site of Inhibition of AMPA Receptors: Substitution of One and Two Methyl Groups at the 4-Aminophenyl Ring of 2,3-Benzodiazepine and Implications in the â€œEâ€•Site. ACS Chemical Neuroscience, 2015, 6, 1371-1378.	1.7	7
12	Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation. Bioorganic and Medicinal Chemistry, 2015, 23, 7053-7060.	1.4	28
13	Synthesis and Biological Evaluation of Papainâ€Family Cathepsinâ€…Lâ€Like Cysteine Protease Inhibitors Containing a 1,4â€Benzodiazepine Scaffold as Antiprotozoal Agents. ChemMedChem, 2014, 9, 1817-1825.	1.6	30
14	Peptideâ€Based Proteasome Inhibitors in Anticancer Drug Design. Medicinal Research Reviews, 2014, 34, 1001-1069.	5.0	46
15	Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. European Journal of Medicinal Chemistry, 2014, 83, 1-14.	2.6	27
16	Development of Novel Selective Peptidomimetics Containing a Boronic Acid Moiety, Targeting the 20S Proteasome as Anticancer Agents. ChemMedChem, 2014, 9, 1801-1816.	1.6	16
17	Identification of a new series of amides as non-covalent proteasome inhibitors. European Journal of Medicinal Chemistry, 2014, 76, 1-9.	2.6	25
18	Development of peptidomimetic boronates as proteasome inhibitors. European Journal of Medicinal Chemistry, 2013, 64, 23-34.	2.6	34

#	Article	IF	Citations
19	Development of Rhodesain Inhibitors with a 3â€Bromoisoxazoline Warhead. ChemMedChem, 2013, 8, 2070-2076.	1.6	37
20	Synthesis of benzothiazole derivatives and their biological evaluation as anticancer agents. Medicinal Chemistry Research, 2012, 21, 2644-2651.	1.1	27
21	Mechanism of Inhibition of GluA2 AMPA Receptor Channel Opening by 2,3-Benzodiazepine Derivatives: Functional Consequences of Replacing a 7,8-Methylenedioxy with a 7,8-Ethylenedioxy Moiety. Biochemistry, 2012, 51, 1787-1795.	1.2	17
22	Synthesis and Molecular Modeling Studies of Derivatives of a Highly Potent Peptidomimetic Vinyl Ester as Falcipainâ€2 Inhibitors. ChemMedChem, 2012, 7, 1594-1600.	1.6	27
23	Development of Novel Peptidomimetics Containing a Vinyl Sulfone Moiety as Proteasome Inhibitors. ChemMedChem, 2011, 6, 1228-1237.	1.6	47
24	Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 2058-2065.	2.6	30
25	Falcipainâ€2 inhibitors. Medicinal Research Reviews, 2010, 30, 136-167.	5.0	121
26	Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 4928-4938.	1.4	31
27	Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain. European Journal of Medicinal Chemistry, 2010, 45, 3228-3233.	2.6	34
28	Synthesis, Chiral Resolution and Pharmacological Evaluation of a 2,3-Benzodiazepine-Derived Noncompetitive AMPA Receptor Antagonist. ChemMedChem, 2009, 4, 415-420.	1.6	1
29	Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 6505-6511.	1.4	28
30	Novel Peptidomimetics Containing a Vinyl Ester Moiety as Highly Potent and Selective Falcipain-2 Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 2157-2160.	2.9	73
31	Nonpeptidic Vinyl and Allyl Phosphonates as Falcipainâ€2 Inhibitors. ChemMedChem, 2008, 3, 1030-1033.	1.6	44
32	Structureâ€“activity study of 2,3-benzodiazepin-4-ones noncompetitive AMPAR antagonists: Identification of the 1-(4-amino-3-methylphenyl)-3,5-dihydro-7,8-ethylenedioxy-4H-2,3-benzodiazepin-4-one as neuroprotective agent. Bioorganic and Medicinal Chemistry, 2008, 16, 2200-2211.	1.4	23
33	Mechanism of Inhibition of the GluR2 AMPA Receptor Channel Opening by 2,3-Benzodiazepine Derivatives. Biochemistry, 2008, 47, 1061-1069.	1.2	22
34	Development of Peptidomimetics with a Vinyl Sulfone Warhead as Irreversible Falcipain-2 Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 988-996.	2.9	196
35	Enantioseparation, absolute configuration determination, and anticonvulsant activity of (Â±)-1-(4-aminophenyl)-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-one. Chirality, 2007, 19, 16-21.	1.3	3
36	Novel Peptidomimetic Cysteine Protease Inhibitors as Potential Antimalarial Agents. Journal of Medicinal Chemistry, 2006, 49, 3064-3067.	2.9	71

#	Article	IF	Citations
37	Synthesis, Chiral Resolution, and Enantiopharmacology of a Potent 2,3-Benzodiazepine Derivative as Noncompetitive AMPA Receptor Antagonist. Journal of Medicinal Chemistry, 2006, 49, 575-581.	2.9	35
38	New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 167-170.	1.0	23
39	Synthesis of Novel 3-(Alkylcarbamoyl)-2-aryl-1,2-dihydro-6,7-(methylenedioxy)-3H-quinazolin-4-ones as Anticonvulsant Agents. Chemistry and Biodiversity, 2006, 3, 304-311.	1.0	4
40	Synthesis of 2-semicarbazonomethyl-4,5-methylenedioxyphenylacetic acids as anticonvulsant agents. Il Farmaco, 2005, 60, 231-235.	0.9	6
41	1-Aryl-6,7-methylenedioxy-3H-quinazolin-4-ones as Anticonvulsant Agents.. ChemInform, 2004, 35, no.	0.1	0
42	Design of 1-substituted 2-arylmethyl-4,5-methylenedioxybenzene derivatives as antiseizure agents. Bioorganic and Medicinal Chemistry, 2004, 12, 3703-3709.	1.4	10
43	1-Aryl-6,7-methylenedioxy-3 H -quinazolin-4-ones as anticonvulsant agents. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4427-4430.	1.0	59
44	Synthesis and cytotoxic activity of 1,3-benzodioxole derivatives. Note II. Il Farmaco, 2003, 58, 351-355.	0.9	19
45	Synthesis and Antitumor Activity of 1,3-Benzodioxole Derivatives.. ChemInform, 2003, 34, no.	0.1	0
46	Synthesis and Cytotoxic Activity of 1,3-Benzodioxole Derivatives. Part 2.. ChemInform, 2003, 34, no.	0.1	1
47	Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 443-446.	1.0	17
48	A SIMPLE AND EFFICIENT SYNTHESIS OF GYKI 52466 AND GYKI 52895. Synthetic Communications, 2002, 32, 527-533.	1.1	12
49	Synthesis and antitumor activity of 1,3-benzodioxole derivatives. Il Farmaco, 2002, 57, 853-859.	0.9	31
50	Novel Potent AMPA/Kainate Receptor Antagonists:Â Synthesis and Anticonvulsant Activity of a Series of 2-[(4-Alkylsemicarbazono)-(4-amino- phenyl)methyl]-4,5-methylenedioxyphenylacetic Acid Alkyl Esters. Journal of Medicinal Chemistry, 2002, 45, 4433-4442.	2.9	14
51	7-Chloro-1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole and 1-(2,6-difluorophenyl)-6-methyl-1H,3H-thiazolo[3,4-a]benzimidazole. Acta Crystallographica Section C: Crystal Structure Communications, 2001, 57, 572-574.	0.4	3
52	Synthesis and anticonvulsant activity of novel and potent 1-aryl-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-ones. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 463-466.	1.0	24
53	Synthesis and in vitro antitumour activity evaluation of 1-aryl-1H,3H-thiazolo[4,3-b]quinazolines. European Journal of Medicinal Chemistry, 2000, 35, 1115-1119.	2.6	37
54	Synthesis and Anticonvulsant Activity of Novel and Potent 6,7-Methylenedioxyphthalazin-1(2H)-ones. Journal of Medicinal Chemistry, 2000, 43, 2851-2859.	2.9	193

#	Article	IF	Citations
55	Synthesis and Anticonvulsant Activity of Novel and Potent 2,3-Benzodiazepine AMPA/Kainate Receptor Antagonists. Journal of Medicinal Chemistry, 1999, 42, 4414-4421.	2.9	48
56	Synthesis and anticonvulsant activity of new 2,3-benzodiazepines as AMPA receptor antagonists. Il Farmaco, 1999, 54, 178-187.	0.9	27
57	7,8-Methylenedioxy-4H-2,3-benzodiazepin-4-ones as novel AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 971-976.	1.0	39
58	1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones:Â Novel AMPA Receptor Antagonists. Journal of Medicinal Chemistry, 1997, 40, 1258-1269.	2.9	88
59	Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 48-55.	1.4	40
60	Separation of the enantiomers of anticonvulsant tricyclic pyrroloimidazolones by enantioselective HPLC. A chiral recognition model and a chiroptical study. Tetrahedron: Asymmetry, 1996, 7, 2577-2584.	1.8	12
61	GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice. European Journal of Pharmacology, 1995, 294, 411-422.	1.7	63
62	Anticonvulsant activity of pyrrolo[1â€²,2â€²:1,2]imidazo[4,5-b]pyridines, pyrrolo[2â€²,1â€²:2,3]imidazo[4,5-c] pyridines and pyrrolo[2,1-f]purines in DBA/2 mice. General Pharmacology, 1994, 25, 1027-1031.	0.7	8
63	Compounds with potential anti-tumor activity VII. Synthesis and anti-tumor activity of 1-aryl-N,Nâ€²-di(1,3,4-thiadiazol-2-yl)methylenediamines. European Journal of Medicinal Chemistry, 1989, 24, 131-135.	2.6	6
64	Synthesis and anticonvulsant properties of 2,3,3a,4-tetrahydro-1H-pyrrolo[1,2-a]benzimidazol-1-ones. Journal of Medicinal Chemistry, 1989, 32, 93-95.	2.9	35
65	Synthesisabd Characerization of Isomeric 2,3,3a,4-Tetrahydro-1H-pyrrolo[1,2-a]benzimidazol-1-ones from 1,2-Phenylenediamines and 3-Acylpropionic Acids. Heterocycles, 1988, 27, 93.	0.4	14